论文部分内容阅读
目的:探讨儿童急性髓系白血病对于大剂量阿糖胞苷的耐受性,为临床用药提供指导。方法:从我院2007年1月～2011年1月收治的儿童急性髓系白血病患者中选取40例,将其作为临床研究对象,随机分成A、B两组,每组均20例患者。两组都给予大剂量阿糖胞苷,A组患者给予体表面积3 g/m2用量;B组患者给予体表面积2 g/m2用量。一周后,分别观察两组急性髓系白血病儿童的治疗效果、神经系统毒性和副作用。结果:治疗一周后,A组患者贫血例数2例(10.00%)较B组患者贫血例数8例(40.00%)少,A组患者所表现的神经毒性头疼、嗜睡、淡漠及惊厥方面较B组患者严重,A组患者所表现的副作用眼球震颤、轮替运动障碍、共济失调均较B组患者严重。结论:大剂量阿糖胞苷虽具有更好的疗效,基本耐受但其不良反应相对严重。
Objective: To investigate the tolerance of childhood acute myeloid leukemia to high-dose cytarabine and provide guidance for clinical use. Methods: Forty children with acute myeloid leukemia from January 2007 to January 2011 in our hospital were selected as clinical study subjects and randomly divided into A and B groups, 20 patients in each group. Both groups were given high doses of cytarabine, patients in group A were given a dosage of 3 g / m2 of body surface area, while those in group B were given 2 g / m2 of body surface area. One week later, the therapeutic effects, nervous system toxicity and side effects of children with acute myeloid leukemia were observed respectively. Results: After treatment for one week, the number of anemia cases in group A was less than that in group B (10.00%), 8 cases (40.00%) less than those in group B. The neurotoxicity symptoms such as headache, drowsiness, apathy and convulsion in group A were less than those in group B Patients in group B were severe, and those in group A had nauseas, nystagmus, ataxia and ataxia compared with patients in group B. Conclusion: The high dose of cytarabine has better curative effect and basic tolerance, but its adverse reaction is relatively serious.